MoCRA vs Canada CNF: A Side by Side for Sellers

Selling into both Canada and the US means dealing with two regimes that sound similar from a distance, facility registration here, product listing there, notification form here, and turn out to be structured quite differently once you get into the details. Worth laying them side by side rather than assuming one is a lighter version of the other.

The core structural difference

Canada's system is a per-product notification. You file a Cosmetic Notification Form through the Cosmetic Notification System for each product, and Health Canada receives it as a notice, not an approval request. It's due within 10 days of first sale, and you get a Cosmetic Notification number back as your proof of filing.

MoCRA, the Modernization of Cosmetics Regulation Act passed in 2022, works at two levels: facility registration and product listing, both with the FDA. Facility registration is about where the product is made, product listing is about what the product is. Some small businesses are exempt from these requirements, which is a category worth checking carefully rather than assuming applies to you by default.

Side-by-side comparison

Dimension	Canada (CNF)	US (MoCRA)
What's being filed	Individual product notification	Facility registration + product listing
Who files	The seller	The seller, via a named responsible person
Timing	Within 10 days of first sale	Per current FDA guidance, check directly
Result	Cosmetic Notification (CN) number	Registration/listing confirmation
Ingredient data	INCI name with concentration or range	Ingredient list as part of listing
Safety documentation	Supports the notification	Formal safety substantiation required
Adverse events	Not a standalone recordkeeping mandate in the same form	Adverse event recordkeeping is a named requirement
Small business treatment	No blanket small-business exemption from filing	Some small businesses exempt from registration/listing
Named accountable person	Not a distinct named role	Named "responsible person" required

Where the two regimes genuinely differ in spirit

Canada's notification model puts the emphasis on transparency after the fact: you tell the regulator what's in the product and how much, using standardized INCI names, and the Cosmetic Ingredient Hotlist tells you what's prohibited or restricted going in. It's lightweight by design, a notice rather than an approval gate.

MoCRA leans more heavily into ongoing accountability. The named responsible person requirement means a specific party is on record as answerable for the product. Safety substantiation is a formal, explicit requirement rather than something implied by the notification. Adverse event recordkeeping is its own named obligation, meaning you need a system for logging and tracking complaints and incidents tied to the product, not just a formula file.

A practical read for someone selling in both markets

1. Don't assume ingredient compliance transfers. An ingredient permitted on Canada's Hotlist at a given level isn't automatically fine under FDA cosmetic ingredient rules, and vice versa. Check both.
2. Build your safety substantiation once, use it twice. The underlying safety reasoning you'd want for MoCRA compliance is good practice to have on hand for Canada too, even though Canada's filing structure doesn't demand it in the same explicit form.
3. Name your responsible person deliberately for the US. This isn't a formality. It's a specific accountable role the FDA expects to be able to reach.
4. Set up adverse event tracking before you need it. Waiting until a complaint comes in to build a recordkeeping system is the wrong order of operations.
5. Remember sunscreen is a different animal entirely in the US, regulated as an OTC drug rather than a cosmetic, which is a distinction Canada's cosmetic framework doesn't map onto the same way.

A word on the exemptions

MoCRA's small business exemptions from registration and listing are a meaningful detail, but they're also easy to misread as a blanket "small makers don't need to worry about this." The exemption criteria are specific, and safety substantiation and adverse event obligations under MoCRA are not necessarily waived just because registration is. If you think you might qualify, confirm against current FDA guidance rather than assuming based on headcount or revenue alone.

Keeping both regimes straight

The practical trap is treating one country's paperwork as a template for the other's. They ask different questions, in different formats, on different timelines, even when the underlying goal, making sure a cosmetic product is safe and properly disclosed, is the same. Cosmetic Comply currently handles Canada notifications end to end, mapping ingredients to INCI and CAS, screening against the Hotlist, and filing the CNF with a compliance reviewer in the loop, and US listing support is on the roadmap. If you're selling into both markets today, keep your ingredient data in one clean, INCI-and-CAS-mapped source, since that's the piece both filings actually share, and build the market-specific parts, responsible person, safety substantiation, adverse event systems, around it separately for each.